The Use of DPP-4 Inhibitors in Short Bowel Syndrome

Phase 4TerminatedNCT02653131

Stanley Dudrick's Memorial Hospital8 enrolled

Overview

The inhibition of Dipeptidyl peptidase-4 should increase the concentration of glucagone-like peptide 1 and 2, and the increase of the latter should increase the absorptive capacity of the intestine.

The only effective (to some extend drug) in short bowel syndrome is Glucacone-like peptide 4. Its price is, however, to high to really change the treatment strategy for intestinal failure. The Dipeptidyl peptidase-4 inhibitor, which a drug which is commonly used in the treatment of diabetes mellitus type II, should increase the concentration of glucagone-like peptide 1 and 2, and the increase of the latter should increase the absorptive capacity of the intestine.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Short Bowel Syndrome

Interventions

Dipeptidyl peptidase-4 inhibitorDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patients receiving home parenteral nutrition (HPN) because of short bowel syndrome for at least 12 months * stable metabolic status * benign disease Exclusion Criteria: * HPN \< 12 months * metabolically unstable * cancer as the reason for intestinal failure

Locations (1)

Stanley Dudrick's Memorial Hospital

Skawina, Poland

Outcomes

Primary Outcomes

Improvement of intestinal absorption

the use of DPP-4 inhibitor results in the better intestinal absorption

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.